What is Leqvio?
Leqvio contains the active substance inclisiran.1
Inclisiran lowers the amount of LDL ('bad' cholesterol),1 which can cause heart disease and circulation problems if levels are elevated. 2
What is it used for?
Leqvio is indicated as adjunct to diet and maximally tolerated statin therapy for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia (HeFH)) to reduce low-density lipoprotein cholesterol (LDL-C).1
Leqvio reduces LDL-C and is expected to improve cardiovascular outcomes.1
Key benefits for Leqvio:
Effective and long-term LDL-C reduction by 2 maintenance doses per year 1
Administration by a healthcare professional gives control over adherence1,2
Well tolerated,3 and no special storage conditions (no freezing)2
The complete Leqvio approach
Leqvio® API
Leqvio® API
References
Egyptian Drug Authority (EDA). Leqvio leaflet approval date: 2/4/2024.
Leqvio, Summary of product charactristics (SMPC). available at: https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_en.pdf. last accessed: 11/6/2025
Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. Journal of the American College of Cardiology. 2021 Mar 9;77(9):1182-93.
Approved by Egyptian Drug Authority: HF0424OA4729/092025. Invalidation date: 23/09/2027.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at: www.edaegypt.gov.eg
Image
|
HF0424OA4729/092025 |
Adverse Events Reporting We encourage using the following Electronic reporting tool for reporting into the safety database directly: |